RxDoctor Payments Data

Nika Jani, MD

Internal Medicine · Woodbridge, VANPI 1194995605

Payments from drug & device makers

$1,984in general payments, 2019–2025

Across 110 payments — averaging $18.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$393
  • Lilly USA, LLC$386
  • Novo Nordisk$328
  • Pfizer$146
  • Currax Pharmaceuticals LLC$124
  • Exact Sciences$105
  • plus $502 from 10 others

What the payments were for

  • Food & beverage$1,94998%
  • Education$352%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,984 in reported general payments places this provider in the 80th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$77,533
Medicare patients
112
Services billed
744

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide43$70,019
FarxigaDapagliflozin Propanediol28$35,690
MounjaroTirzepatide24$32,560
JanuviaSitagliptin Phosphate13$19,879
Rosuvastatin Calcium172$2,094
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$1,830
Ezetimibe74$1,155
Levothyroxine Sodium113$1,144
Atorvastatin Calcium146$991
Famotidine36$913
Montelukast Sodium71$880
Amlodipine Besylate163$654
Metformin Hcl118$608
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide17$548
Azelastine Hcl15$518

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$328$70,01943 claims
AstraZenecaFarxiga$393$35,69028 claims
Lilly USA, LLCMounjaro$386$32,56024 claims
MerckJanuvia$96$19,87913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Woodbridge

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →